IMNM Q4 2024 Earnings — Immunome, Inc. Revenue & Financial Results | Market Cap Arena

IMNMImmunome, Inc.

$2B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-28.4% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$83M-3030.3% margin

Net Income

-$80M-2930.9% margin

EPS (Diluted)

$-1.28

QoQ Revenue Growth

-5.9%

Cash Flow

Operating Cash Flow

-$42M

Free Cash Flow

-$43M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$240M

Total Liabilities

$59M

Stockholders' Equity

$181M

Cash & Equivalents

$143M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$4M	-28.4%
Gross Profit	$3M	$4M	-28.4%
Operating Income	-$83M	-$95M	+12.3%
Net Income	-$80M	-$93M	+13.4%